```html

Xerophthalmic Corneal Ulcer – A Complete Medical Guide

Overview

Xerophthalmic corneal ulcer is an open sore on the cornea that develops in the setting of severe ocular surface dryness (xerophthalmia). The lack of adequate tear film, combined with inflammation, leads to breakdown of the corneal epithelium and, if untreated, can progress to a full‑thickness ulcer.

• Who it affects: Primarily adults over 50 years of age, but can occur at any age in people with chronic dry‑eye disease, vitamin A deficiency, or autoimmune disorders such as Sjögren’s syndrome.
• Prevalence: Xerophthalmia‑related corneal ulcers account for roughly 10‑15 % of all infectious and non‑infectious corneal ulcers in tertiary eye‑care centers in the United States and Europe (American Academy of Ophthalmology, 2022). In low‑resource settings where vitamin A deficiency is common, the condition is more prevalent, affecting up to 1 % of children under 5 years in some rural Asian populations (WHO, 2021).

Symptoms

The presentation can be subtle early on, progressing to severe pain and visual loss if the ulcer deepens.

• Ocular discomfort: Burning, gritty sensation, or a feeling that something is “stuck” in the eye.
• Redness: Diffuse injection of the bulbar conjunctiva, often more prominent at the limbus.
• Tearing or paradoxical dry eye: Excessive reflex tearing that does not relieve the dryness.
• Photophobia: Light sensitivity that worsens with bright environments.
• Blurred vision: Usually intermittent at first; may become constant as the ulcer enlarges.
• Foreign‑body sensation: The ulcer’s irregular surface can mimic a sand‑grain feeling.
• Visible epithelial defect: On slit‑lamp exam, an area of loss of the normal glossy corneal surface appears as a gray or white spot with rolled edges.
• Discharge: Minimal purulent or mucoid discharge if secondary infection develops.
• Reduced tear meniscus height: Clinically observed as a shallow tear lake on the lower lid margin.

Causes and Risk Factors

While the ulcer itself is a downstream event, several upstream factors set the stage for xerophthalmic corneal ulceration.

Primary Causes

• Severe aqueous‑deficient dry eye (xerophthalmia): Failure of lacrimal glands to produce enough tear fluid (e.g., Sjögren’s syndrome, graft‑versus‑host disease).
• Vitamin A deficiency: Impairs mucin production and epithelial differentiation, leading to keratinization and ulcer formation.
• Exposure keratopathy: Incomplete eyelid closure during sleep (lagophthalmos) or facial nerve palsy.
• Topical medication toxicity: Prolonged use of preserved eye drops (especially with benzalkonium chloride) can disrupt the epithelial barrier.
• Inflammatory ocular surface disease: Conditions such as ocular rosacea, meibomian gland dysfunction, or chronic blepharitis.

Risk Factors

• Age > 50 years
• Female sex (higher prevalence of autoimmune dry‑eye disorders)
• Systemic autoimmune disease (Sjögren’s, rheumatoid arthritis, systemic lupus erythematosus)
• History of ocular surgery (e.g., cataract, LASIK) that alters tear dynamics
• Contact lens wear, especially extended‑wear lenses that reduce oxygen supply
• Environmental extremes – low humidity, wind, air‑conditioning
• Nutritional deficiency – inadequate intake of vitamin A, omega‑3 fatty acids

Diagnosis

Prompt, accurate diagnosis is essential to preserve vision.

Clinical Examination

• Visual acuity testing: Establish baseline vision.
• Slit‑lamp biomicroscopy: The gold‑standard for detecting epithelial defects, stromal thinning, and infiltrates.
• Fluorescein staining: Instillation of fluorescein dye highlights the ulcer as a bright green area, allowing measurement of size (mm) and depth.
• Tear‑film assessment: Schirmer I test (<5 mm/5 min suggests aqueous deficiency) and tear‑film break‑up time (TBUT < 5 seconds indicates instability).

Ancillary Tests

• Anterior segment optical coherence tomography (AS‑OCT): Provides cross‑sectional imaging to quantify stromal depth and monitor healing.
• Corneal confocal microscopy: Detects early cellular changes and presence of pathogens when infection is suspected.
• Microbiological cultures: Swab of the ulcer base if there is a purulent discharge or risk of bacterial/fungal infection; sent for Gram stain, culture, and sensitivity.
• Serum vitamin A level: Particularly in patients from regions with known deficiency.
• Autoimmune panel: ANA, SSA/SSB antibodies when Sjögren’s or other systemic disease is suspected.

Treatment Options

Treatment is multimodal and aims to restore tear homeostasis, eradicate infection, promote epithelial healing, and prevent scarring.

Medical Management

• Lubrication: Preservative‑free artificial tears 4–6 times daily; ointments at night to maintain a moist environment.
• Anti‑inflammatory therapy:
  • Cycloplegic agents (e.g., cyclopentolate 1 %) to reduce ciliary spasm.
  • Topical corticosteroids (e.g., prednisolone acetate 1 %) in low‑dose regimens for stromal inflammation—use only under close supervision.
  • Topical cyclosporine A 0.05 % or lifitegrast 5 % for chronic aqueous‑deficient dry eye.
• Antimicrobial therapy: Empiric broad‑spectrum antibiotic drops (e.g., moxifloxacin 0.5 % q.i.d.) while awaiting cultures. Adjust based on sensitivities.
• Vitamin A supplementation: Oral retinol 10,000 IU daily for 2–3 weeks, then maintenance dosing per WHO guidelines for deficiency.
• Autologous serum eye drops: 20 %–50 % concentration provides growth factors and tear‑film proteins; useful for persistent epithelial defects.

Procedural Interventions

• Punctal occlusion: Silicone plugs or thermal cautery to retain tears on the ocular surface.
• Amniotic membrane transplantation (AMT): Acts as a biological bandage, reduces inflammation, and promotes epithelial migration.

Therapeutic contact lens (bandage CL): Silicone‑hydrogel lenses protect the ulcer and improve comfort; replaced frequently to avoid infection.

Debridement: Gentle removal of necrotic tissue under aseptic conditions to stimulate healing.

Laser-assisted corneal cross‑linking (CXL): Considered for peripheral ulcers prone to stromal melt; strengthens corneal collagen.

Lifestyle and Adjunctive Measures

• Humidifier use in dry indoor environments (relative humidity 45‑55 %).
• Protective eyewear outdoors to shield from wind and dust.
• Omega‑3 fatty‑acid supplementation (1 g EPA/DHA daily) to improve meibomian gland function.
• Smoking cessation – tobacco smoke reduces tear production and impairs healing.

Living with Xerophthalmic Corneal Ulcer

Managing the condition day‑to‑day can reduce recurrences and improve quality of life.

• Adhere to medication schedule: Missing drops can allow the ulcer to worsen.
• Maintain eyelid hygiene: Warm compresses and lid scrubs (e.g., diluted baby shampoo) twice daily to treat blepharitis.
• Regular follow‑up: Ophthalmology visits every 1‑2 weeks until the ulcer fully resolves, then every 3‑6 months.
• Dietary considerations: Eat foods rich in vitamin A (carrots, sweet potatoes, leafy greens) and zinc (pumpkin seeds, beans).
• Monitor visual changes: Keep a log of any new blur, halos, or increased glare and report promptly.
• Eye protection during sleep: Moisture goggles or eyelid taping for patients with lagophthalmos.

Prevention

Preventive strategies focus on preserving tear film integrity and preventing epithelial breakdown.

• Screen for dry eye early: Adults over 40 with symptoms should have a Schirmer test and TBUT.
• Optimize systemic disease control: Adequate treatment of Sjögren’s, rheumatoid arthritis, or diabetes reduces ocular surface inflammation.
• Limit preservative exposure: Use preservative‑free formulations for chronic therapy.
• Environmental control: Avoid direct airflow from fans, air‑conditioners, or heaters; use protective eyewear in windy conditions.
• Nutritional adequacy: Ensure daily intake of at least 900 µg retinol activity equivalents (RAE) of vitamin A and 1.3 g omega‑3 fatty acids.
• Regular eye exams: Early detection of meibomian gland dysfunction or lid malposition allows timely intervention.

Complications

If left untreated or inadequately managed, xerophthalmic corneal ulcer can lead to serious outcomes.

• Corneal stromal melt: Progressive thinning that may perforate the globe.
• Secondary bacterial, fungal, or viral infection: Can accelerate tissue loss.
• Scarring and neovascularization: Leads to permanent visual impairment and glare.
• Topical corticosteroid‑induced glaucoma or cataract: Requires monitoring when steroids are used.
• Permanent vision loss: Particularly if the ulcer involves the visual axis.

When to Seek Emergency Care

---

Sources: American Academy of Ophthalmology (AAO) Preferred Practice Patterns 2022; Mayo Clinic. “Dry eye.” 2023; World Health Organization. “Vitamin A deficiency.” 2021; National Eye Institute (NEI). “Corneal Ulcer.” 2022; Cleveland Clinic. “Sjögren’s syndrome and ocular involvement.” 2023; peer‑reviewed articles in Ophthalmology and Cornea journals, 2020‑2024.

```